Rapid method of generating live attenuated vaccines

Patent metadata

Field	Value
Publication number	US-11865083-B2
Application number	US-202117249329-A
Country	US
Kind code	B2
Filing date	Feb 26, 2021
Priority date	Apr 14, 2016
Publication date	Jan 9, 2024
Grant date	Jan 9, 2024

Abstract

The present invention relates to a method of generating a live attenuated vaccine. The present invention also relates to a live attenuated vaccine produced according to the method of the invention.

First claim

The invention claimed is:

1. A vaccine comprising a nucleic acid sequence encoding the genome of a maladapted Zika virus, wherein the nucleic acid sequence comprises a sequence selected from the group consisting of SEQ NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, and SEQ ID NO: 42.

2. The vaccine of claim 1 , wherein the nucleic acid sequence is a DNA sequence or a messenger RNA (mRNA) sequence.

3. The vaccine of claim 1 , wherein the nucleic acid sequence is SEQ ID NO: 40.

4. The vaccine of claim 1 , wherein the maladapted Zika virus is generated by passaging a Zika virus at least once in a cell or cell line that is of a species distinct from the intended recipient of the vaccine.

5. The vaccine of claim 1 , wherein the maladapted Zika virus is generated by passaging a Zika virus for four rounds in Vero cells, followed by passaging for a single round in C6/36 cells.

6. The vaccine of claim 5 , wherein the Zika virus is a French Polynesian strain of Zika virus.

7. The vaccine of claim 6 , wherein the Zika virus strain is PF13/251013-18.

8. The vaccine of claim 1 , wherein the vaccine is capable of eliciting sterilizing immunity in a subject.

9. The vaccine of claim 1 , wherein the vaccine is a live attenuated vaccine.

10. A method of preventing or treating a Zika infection in a subject comprising administering to the subject an effective amount of the vaccine of claim 1 .

11. The method of claim 10 , wherein the administering comprises intradermal, intramuscular or subcutaneous injection.

12. The method of claim 10 , wherein the vaccine is administered alone or in combination with a buffer.

13. The method of claim 10 , wherein the vaccine is administered to the subject in a single dose or in multiple doses.

14. A method of inducing sterilizing immunity to a Zika infection in a subject comprising administering to the subject an effective amount of the vaccine of claim 1 .

15. The method of claim 14 , wherein the administering comprises intradermal, intramuscular or subcutaneous injection.

16. The method of claim 14 , wherein the vaccine is administered alone or in combination with a buffer.

17. The method of claim 14 , wherein the vaccine is administered to the subject in a single dose or in multiple doses.

Assignees

• Nat Univ Singapore

Inventors

• Ooi Eng Eong
• Goh Kenneth
• Kwek Swee Sen
• Tang Choon Kit

Classifications

• A61K39/12 Primary

  Viral antigens · CPC title

• A61K2039/5254

  avirulent or attenuated · CPC title

• C12N2770/24121

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title

• C12N2770/24122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2770/24134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title